We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Harmless Bacteria Thrive in Patients with Inflammatory Bowel Disease

By LabMedica International staff writers
Posted on 26 May 2015
Image: The CARY 50 BIO UV-Visible Spectrophotometer (Photo courtesy of Agilent Technologies).
Image: The CARY 50 BIO UV-Visible Spectrophotometer (Photo courtesy of Agilent Technologies).
The survival and proliferation of usually harmless Escherichia coli in the gut of inflammatory bowel disease patients may now be better understood, as fundamental mechanism through which the bacteria can thrive during flare-ups has been defined.

Some strains of E. coli normally live in the intestines of humans, and are important for a healthy digestive tract, but for people who suffer from inflammatory bowel diseases (IBD), these innocuous strains may proliferate during a flare-up and further contribute to disease and discomfort.

Scientists at Pennsylvania State University (University Park, PA, USA) and their colleagues studied the interactions between enterobactin, myeloperoxidase and lipocalin 2 and how they regulate E. coli in the intestine. Enterobactin (Ent) is an iron-loving chemical secreted by E. coli that takes iron from host proteins in the body and aids the proliferation of E. coli. Myeloperoxidase (MPO) is an antibacterial protein that white blood cells produce to fight bacteria, however Ent inhibits MPO from doing its job. Lipocalin 2 (Lcn2) is another protein, also produced by white blood cells, that gathers up Ent so that bacteria fail to obtain a sufficient amount of iron for their survival.

Spectral analysis of lactoperoxidase (LPO) during the oxidation of Ent, 2,3-dihydroxybenzoic acid (DHBA) and 4-aminobenzoic hydrazide (ABAH) was recorded at 412 nm using CARY50BIO UV-Visible Spectrophotometer (Agilent Technologies; Santa Clara, CA, USA). By using various techniques the team found that Lcn2 can counter the effects of Ent on MPO. They were able to define a new defense mechanism used by E. coli residing in a human or animal host, the inhibition of MPO by Ent. These findings define a fundamental mechanism by which E. coli surpasses the host innate immune responses during inflammatory gut diseases and gains a distinct survival advantage.

Matam Vijay-Kumar, PhD, an assistant professor of nutritional sciences and medicine and lead author of the study said, “Several types of inflammatory bowel disease are characterized by expansion of the opportunistic E. coli in the gut. However, the mechanisms by which E. coli can thwart the hostile host innate immune system are poorly understood. Identifying these mechanisms will help to reduce the E. coli burden in the inflamed gut and prevent chronic extra-intestinal diseases. We have to find a way to identify the drugs which can inhibit or degrade secreted enterobactin. Alternatively, since MPO is known to be pro-inflammatory not only in IBD but also in other inflammatory diseases, it may be possible to develop enterobactin-based drugs to alleviate inflammatory pathways.” The study was published on May 12, 2015, in the journal Nature Communications.

Related Links:

Pennsylvania State University
Agilent Technologies 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Automatic Hematology Analyzer
CF9600

Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more